CJC-1295 side effects: what the literature reports

The short version: most CJC-1295 side effects are mild and dose-related — but a few warrant a clinician call quickly. Here is what the published literature describes.

TL;DR

The most common side effects are injection-site reactions, flushing, headache, and mild water retention.
Sustained growth hormone elevation can affect blood sugar — clinicians monitor it on therapy.
A small set of effects (joint pain, persistent swelling, vision changes) require prompt medical review.

What it is

CJC-1295 is a modified version of growth hormone-releasing hormone (in plain English: a small protein that signals the pituitary to release growth hormone). Two forms exist: with DAC (a chemical anchor that extends half-life to about a week) and without DAC (also called modified GRF 1-29, lasting hours). The side effect picture differs slightly between the two, mostly because of how long the signal stays active.

How side effects happen

Think of GHRH receptors as a doorbell. Sermorelin and short-acting CJC-1295 ring the doorbell once. CJC-1295 with DAC keeps the doorbell pressed for days. A longer signal raises the chance of growth hormone over-correction — which is why most reported side effects relate to fluid balance, blood sugar, and joint comfort.

What the research says

A 2006 Phase I trial in healthy adults reported headache, flushing, and injection-site reactions as the most common adverse events (Teichman et al., J Clin Endocrinol Metab, 2006). A follow-up dose-ranging study described mild water retention and transient muscle stiffness, especially at higher dose levels (Ionescu & Frohman, J Clin Endocrinol Metab, 2006). About 1 in 10 trial participants experienced flushing in the first week. These are short trials in healthy adults — long-term safety data is limited.

What to know before considering it

Side effects to mention to the prescribing clinician right away include persistent joint pain, carpal-tunnel-style hand tingling, swelling in the feet that does not resolve overnight, blurred vision, or new high blood sugar readings. Most people taking compounded CJC-1295 do not experience these — but the framework is to monitor early, not to wait. People with active cancer, uncontrolled diabetes, or untreated thyroid disease are typically not candidates.

The Halftime POV

Side effects are the test of whether a peptide protocol is being run carefully. CJC-1295 with DAC is convenient (once-weekly), but the longer signal makes baseline labs and follow-up labs non-negotiable. Speed of dose escalation matters more than the dose itself.

Related reading:

FAQ

Q: What are the most common CJC-1295 side effects? A: Published trials report injection-site reactions (redness, mild swelling), flushing, headache, and water retention as the most common effects. Most resolve within the first one to two weeks of therapy.

Q: Does CJC-1295 cause insulin resistance? A: Sustained activation of the growth hormone axis can mildly elevate blood sugar in some people. Clinicians monitor fasting glucose and HbA1c during therapy. People with poorly controlled diabetes are typically not candidates.

Q: Is CJC-1295 FDA-approved? A: No. CJC-1295 is not FDA-approved as a finished product. It is prescribed off-label and prepared by state-licensed 503A compounding pharmacies. The compounded version is not FDA-approved.

Disclaimer

This article is educational and is not medical advice. Compounded medications are not FDA-approved. Clinical outcomes depend on individual factors and require physician evaluation. Results vary. Halftime Health is launching soon — join the waitlist to get updates.

Get updates

Halftime Health is launching soon. We’ll share what we learn along the way — the research, the regulations, the real-world trade-offs. Join the waitlist and we’ll email you when we’re live.